BNP PARIBAS ARBITRAGE/CALL/MODERNA/130/0.1/20.09.24 | Real-time Euronext Paris 11:23:25 2024-05-27 am EDT | ||
| 4.225 EUR | -3.87% |
|
| Current month | +312.68% | ||
| 1 month | +385.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 4.225 | -3.87% |
| 24-05-24 | 4.395 | +8.12% |
| 24-05-23 | 4.065 | +12.76% |
| 24-05-22 | 3.605 | +55.72% |
| 24-05-21 | 2.315 | +0.87% |
Real-time Euronext Paris
Last update May 27, 2024 at 11:23 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| 6N2NB | |
| ISIN | NLBNPFR1YRI3 |
| Date issued | 2024-02-27 |
| Strike | 130 $ |
| Maturity | 2024-09-20 (116 Days) |
| Parity | 10 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.405 € |
|---|---|
| Lowest since issue | 0.6 € |
| Spread | 0.03 € |
| Spread % | 0.71% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- 6N2NB Warrant
